Recently, many reports were published supporting the clinical use of adoptivelytransferred natural killer (NK) cells as a therapeutic tool against cancer, including acutemyeloid leukemia (AML). Our group demonstrated promising clinical response usingadoptive immunotherapy with donor-derived alloreactive KIR-ligand-mismatched NK cellsin AML patients. Moreover, the antileukemic effect was correlated with the dose of infusedalloreactive NK cells (“functional NK cell dose”). Herein, we update the results of ourprevious study on a cohort of adult AML patients (median age at enrollment 64) infirstmorphological complete remission (CR), not eligible for allogeneic stem celltransplantation. After an extended median follow-up of 55.5 months, 8/16 evaluablepatients (50%) are still off-therapy and alive disease-free. Overall survival (OS) and disease-free survival (DFS) are related with the dose of infused alloreactive NK cells (≥2×105/kg)
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters / Parisi, Sarah; Ruggeri, Loredana; Dan, Elisa; Rizzi, Simonetta; Sinigaglia, Barbara; Ocadlikova, Darina; Bontadini, Andrea; Giudice, Valeria; Urbani, Elena; Ciardelli, Sara; Sartor, Chiara; Cristiano, Gianluca; Nanni, Jacopo; Zannoni, Letizia; Chirumbolo, Gabriella; Arpinati, Mario; Lewis, Russell E.; Bonifazi, Francesca; Marconi, Giovanni; Martinelli, Giovanni; Papayannidis, Cristina; Paolini, Stefania; Velardi, Andrea; Cavo, Michele; Lemoli, Roberto M.; Curti, Antonio. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - ELETTRONICO. - 12:(2022), pp. 1-6. [10.3389/fimmu.2021.804988]
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters
Parisi, Sarah;Dan, Elisa;Sinigaglia, Barbara;Ocadlikova, Darina;Giudice, Valeria;Sartor, Chiara;Cristiano, Gianluca;Nanni, Jacopo;Zannoni, Letizia;Chirumbolo, Gabriella;Arpinati, Mario;Lewis, Russell E.;Bonifazi, Francesca;Marconi, Giovanni;Martinelli, Giovanni;Papayannidis, Cristina;Paolini, Stefania;Cavo, Michele;Lemoli, Roberto M.;Curti, Antonio
2022
Abstract
Recently, many reports were published supporting the clinical use of adoptivelytransferred natural killer (NK) cells as a therapeutic tool against cancer, including acutemyeloid leukemia (AML). Our group demonstrated promising clinical response usingadoptive immunotherapy with donor-derived alloreactive KIR-ligand-mismatched NK cellsin AML patients. Moreover, the antileukemic effect was correlated with the dose of infusedalloreactive NK cells (“functional NK cell dose”). Herein, we update the results of ourprevious study on a cohort of adult AML patients (median age at enrollment 64) infirstmorphological complete remission (CR), not eligible for allogeneic stem celltransplantation. After an extended median follow-up of 55.5 months, 8/16 evaluablepatients (50%) are still off-therapy and alive disease-free. Overall survival (OS) and disease-free survival (DFS) are related with the dose of infused alloreactive NK cells (≥2×105/kg)| File | Dimensione | Formato | |
|---|---|---|---|
|
frontiers in immunology.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione
1.52 MB
Formato
Adobe PDF
|
1.52 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
